Purpose Extensive studies have investigated the prognostic value of CD56 for patients with
acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta …

ABSTRACT Objectives Previous study (Br. J. Haematol. 2017; 176: 498) reported that CD56
positive is associated with poor prognosis of patients with intermediate-risk acute myeloid …

Acute myeloid leukemia (AML) is a heterogeneous group of disorders with distinct
characteristics and prognoses. Although cytogenetic changes and gene mutations are …

The aims of this study were to investigate the frequency and prognostic relevance of CD56
expression in patients with acute myeloid leukemia (AML) and to compare the importance of …

Abstract CD56 antigen, a 200–220 kDa cell surface glycoprotein, identified as an isoform of
the neural adhesion molecules (NCAM), has been found frequently expressed in several …

BACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall
survival, lower rates or short complete remission and extramedullary invasion but the results …

Background: The aim of this review was to evaluate the influence of aberrant phenotypes in
prognosis and survival in acute myeloid leukemia (AML) patients by multiparametric flow …

CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic
phenotype and resistance to induction therapy but no inferior survival after risk-adapted …

CD56 expression in acute myeloid leukemia (AML) has been associated with
extramedullary leukemia and multidrug resistance, but its clinical and prognostic …

Background: The expression of CD7 and CD56 in Acute Myeloid Leukaemia was
considered to be a poor prognostic factor for overall survival, complete remission but the …